3 days popular7 days popular1 month popular3 months popular

New data provide evidence that Hexvix can improve the overall survival in bladder cancer patients

Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that a study on the impact of Hexvix on survival in patients has been published in the .

The study investigated the impact on survival in bladder cancer patients of photodynamic diagnosis (PDD)-guided resection (TUR-BT), including that guided by Hexvix (hexaminolevulinate (HAL)).

The findings from this retrospective study of 224 patients demonstrate for the first time that Hexvix guided TUR-BT in bladder cancer patients, who later progressed to requiring radical cystectomy (RC), significantly increased the three year overall survival (p=0.037) and the median three year recurrence free survival (p=0.002) compared to patients in the comparator group.

Dr. Georgios Gakis of the Department of Urology, Eberhard-Karls University at Tuebingen, Germany and lead author, stated: “These data indicate for the first time that improved patient management with HAL-guided TUR-BT can make a difference in outcomes even for those bladder cancer patients who later progress to advanced disease and require radical cystectomy.”

Kjetil Hestdal, President and CEO of Photocure, said: “These exciting data add to the growing clinical evidence that Hexvix/Cysview makes a positive impact on the diagnosis and management of bladder cancer in multiple patient types. We believe the continuously increasing adoption of Hexvix/Cysviewguided TUR-BT will bring significant clinical and health economic benefit to urologists, patients and payers fighting the disease.”

The paper was a retrospective analysis of data from 224 consecutive bladder cancer patients undergoing RC. Of these patients, prior to RC, 66 (29.5%) underwent hexaminolevulinate (HAL)-guided bladder tumor resection (TUR-BT), 23 (10%) 5-aminolevulinate (ALA)-guided TUR-BT and 135 (60.2%) white light (WL)-guided TUR-BT.

Three Year Overall Survival (OS): 74.0% in patients with HAL-TUR-BT compared to 60.9% with ALA-TUR-BT and 56.5% with White Light-guided TUR-BT. (p=0.037 for HAL vs. ALA/WL.)

Median Three Year Recurrence Free Survival (RFS): 77.8% for patients with HAL-based TUR-BT compared to 53.6% for ALA-TUR-BT and 52.5% for White Light-guided TUR-BT. (p=0.002 for HAL vs. ALA or WL.)

Bladder cancer, which affects 550,000 people in the U.S. and 500,000 in Europe has a high recurrence rate, up to 61% in one year and 78% over five years, making the lifetime costs of managing bladder cancer one of the highest of all cancers.


Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy, Georgios Gakis, Theofanis Ngamsri, Steffen Rausch, Johannes Mischinger, Tilman Todenhöfer, Christian Schwentner, Manuel Alexander Schmid, Fahmy Al-Sayed Hassan, Markus Renninger, Arnulf Stenzl, World Journal of Urology, DOI: 10.1007/s00345-015-1485-8, published 17 January 2015.

Source: Photocure ASA